Expression and modulation of the Lewis x antigen (CD15) on the T cell line Molt-4  by Schulze-Forster, Kai & Maurer, H.Rainer
FEBS 19232 FEBS Letters 415 (1997) 25-28 
Expression and modulation of the Lewis x antigen (CD 15) on the 
T cell line Molt-4 
Kai Schulze-Forster, H. Rainer Maurer* 
Institut für Pharmazie der Freien Universität Berlin, Abteilung Pharmazeutische Biochemie, Molekularbiologie und Biotechnologie, Kelchstraße 31, 
D-12169 Berlin, Germany 
Received 17 July 1997 
Abstract The T cell lines Molt-4 and H9 exhibited a 
characteristic distribution of the cell adhesion molecule Lewis x 
(CD15, lacto-A-fucopcntanosc III) showing an unusually broad 
peak by flow cytometry ranging from cells without CD15 to cells 
with high expression. The cytokines IL-1, IL-2, IFN-ß, IFN-γ, 
and TNF-α, known to activate T cells, did not affect CD15 
expression. However, phorbol myristate acetate and the thymic 
peptide extract Thymex-L were able to enhance both the number 
of CD15-positive cells and the median fluorescence. The effects 
of both inducers were dose- and time-dependent. An additive or 
synergistic effect was not seen. These data suggest that phorbol 
esters and distinct thymic peptides can modulate the expression 
of the cell surface antigen CD15. 
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1. Introduction 
The selectin family is involved as part of the cell adhesion 
molecule system in the initial stage of leukocyte extravasation 
[1-3]. E- and P-selectin are expressed on activated endothelia 
and are recognized by various leukocyte populations including 
activated T cells [4,5]. Their counterparts on leukocytes are 
cell surface carbohydrates [6] including the Lewis x antigen 
(CD15, lacto-7V-fucopentanose III). CD15 is found on numer-
ous cellular proteins involved in cellular adhesive events and 
has a broad cellular distribution also on leukocytes [7] and 
tumor cells [8-10]. In addition to its well-recognized adhesive 
role, the engagement of CD 15 results in monocyte activation 
[11] suggesting CD 15 as part of a signaling pathway. Only 
little information is available about the modulation of 
CD 15. In the breast cancer cell line MDA-MB-468 CD 15 
was downregulated by TNF-cc, PMA, IL-1 a, IFN-γ, and all-
trans-Ktmoic acid, whereas l,25(OH)2-vitamin D3 upregu-
lated its expression [12]. In contrast CD15 remained un-
changed after treatment of two human myeloid leukemia 
cell lines (NB4, HL60) with all-fra«i-retinoic acid, bryostatin 
1, or PMA [13]. 
We investigated the T cell leukemia line Molt-4 clone 8 for 
expression of CD15. Molt-4 cells are widely used as a model 
for T lymphocytes and share many features like cytokine se-
cretion [14] and receptor expression [15] with normal T cells. 
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The modulation of CD15 was tested using known cytokines. 
Additionally the phorbol ester PMA was included. PMA has 
been found to enhance IL-2 secretion [14], increase TNF-a 
mRNA production [16] and modulate leukocyte surface anti-
gens [17] of Molt-4 cells. Moreover, since the induction of 
specific cell surface receptor molecules like CD4 and CD8 
on T cells normally takes place in the thymus during T cell 
maturation (reviewed in [18]) and may be mediated by so-
called thymic hormones, we also tested the influence of several 
thymic peptides and extracts on CD 15 modulation. In the 
present study we provide evidence that PMA and a total thy-
mus peptide extract are able to enhance CD 15 expression in 
Molt-4 cells. 
2. Materials and methods 
2.1. Materials 
Thymex-L, TFX, prothymosin oti [19], and thymosin ß4 [20] were 
gifts of Thymoorgan-GmbH (Vienenburg, Germany). Thymex-L is a 
total water extract from juvenile calf thymus, prepared by homoge-
nization, centrifugation, and sterile filtration. The final lyophilisate 
contains 0.6 mg protein/mg, a variety of enzymes, and thymic pep-
tides. TFX (Thymomodulin) is prepared by water extraction of calf 
thymus, centrifugation, 3 times ultrafiltration, and gel filtration. The 
thymic fraction with molecules < 10 kDa contains main peptide com-
ponents around 4200 Da. THFy2 is a chemically defined octapeptide 
isolated from dialysates of calf thymus homogenates [21] (Pharmacia, 
Milan, Italy). TP5 was from Ferring Co. (Kiel, Germany). IL-1, IL-2, 
and TNF-a were from Boehringer Mannheim (Germany). Phorbol 
myristate acetate (PMA) was from Sigma (Deisenhofen, Germany). 
IFN-γ was from Rentschler Co. (Laupheim, Germany). 
2.2. Cell culture 
The cells were maintained in RPMI 1640 medium supplemented 
with 10% fetal calf serum (FCS) and 100 U/ml penicillin/0.1 mg/ml 
streptomycin. The cells were subcultured twice a week and seeded at 
an initial density of 2.5 X105 cells/ml. Cell viability was assessed by 
trypan blue exclusion and found to be routinely > 95%. 
2.3. Cell induction 
7X 105 Molt-4 clone 8 cells were suspended in 1 ml RPMI 1640, 5% 
FCS in a 24-well microtiter plate and treated with the indicated sub-
stances for 24 h at 37°C in a humidified incubator. Subsequently the 
viability was estimated using trypan blue exclusion and the CD 15 
expression was measured using flow cytometry. All experiments 
were repeated at least three times. Representative experiments are 
shown. 
2.4. CD 15 expression by flow cytometry 
2X105 cells were stained with a monoclonal anti-CD15 antibody 
(clone 80H5, Dianova, Hamburg, Germany) for 60 min at room tem-
perature, washed, incubated with FITC-conjugated goat anti-mouse 
IgG antibody (Sigma) for 45 min at 4°C, and washed again. For each 
sample a control reaction omitting the CD 15 antibody was performed. 
Flow cytometric analysis was executed on a FACSCalibur (Becton 
Dickinson) using the CellQuest software. During flow cytometry, 
dead cells and debris were excluded by appropriate scatter gates. 
Control values were subtracted from all samples. 
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Fig. 1. Flow cytometric analysis of CD 15 in Molt-4 and H9 cells. A: Basic expression in Molt-4 cells (solid line); control (dashed line). B: Ba-
sic expression in H9 cells (solid line), control (dashed line). C: Expression in Molt-4 cells after treatment with 1 ng/ml PMA (thick line) and 
800 μg/ml Thymex-L (line); untreated cells (dashed line). D: Expression in Molt-4 cells after treatment with 800 μ§/piι1 Thymex-L (thick line); 
untreated cells (dashed line). 
3. Results 
Molt-4 cells exhibited a characteristic CD 15 distribution on 
flow cytometry: a broad sloping peak containing the majority 
of cells in the range of weak expression (Fig. 1A). While the 
level of expression increased, the number of Molt-4 cells con-
tinuously decreased. Nevertheless cells with extremely high 
expression were also found. This was indicated by the discrep-
ancy between the mean (84.1 relative units) and the median 
(7.0 relative units) fluorescence. For comparison, the expres-
sion of another T cell line was investigated. The expression 
profile of H9 cells shared important features with Molt-4 
cells: the broad peak, most cells with weak expression, but 
cells with a high CD15 level were also present (Fig. IB). The 
number of positive cells (about 30%) was less than the number 
of positive Molt-4 cells (about 60%). 
Several T cell inducing cytokines were tested for their abil-
ity to change CD15 expression in Molt-4 cells (Fig. 2). None 
of them was effective. However, PMA was able to enhance 
both the number of positive cells and the median fluorescence. 
Moreover, different kinds of peptide preparations from calf 
thymus were tested at the concentrations given in Fig. 2: (i) 
oligopeptides (TP5, 5 amino acids; THFy2, 8 amino acids); 
(ii) polypeptides (thymosin β4, 43 amino acids; prothymosin 
a i , 109 amino acids); (iii) aqueous extracts (TFX, < 10 kDa; 
Thymex-L, < 70 kDa). 
Only Thymex-L showed an effect comparable to PMA. Fig. 
1C,D show that both inducers shifted the expression curves of 
Molt-4 cells in the same direction. The treatment mainly en-
hanced the expression of Molt-4 cells with weak constitutive 
CD 15 expression (below 102 relative fluorescence units). 
Whereas PMA treated Molt-4 cells showed a depressed pro-
liferation rate, Thymex-L did not affect cell viability and pro-
liferation. The addition of unspecific proteins such as serum 
albumin was ineffective (data not shown). 
Fig. 3 shows the dose dependence of both activators after 
24 h of incubation. Maximal effects of PMA were reached 
with 1 ng/ml, higher concentrations inhibited the stimulation. 
The variation of PMA concentration between 0.5 and 5 ng/ml 
showed less effect. Using Thymex-L up to 5 mg/ml, the effect 
increased up to 383% of the untreated control. A plateau was 
Fig. 2. Modulation of CD 15 expression in Molt-4 cells by various 
cytokines and immunomodulators The cells were treated for 24 h 
with the indicated substances (all concentrations per ml). Subse-
quently cell surface CD 15 expression was determined by flow cy-
tometry, measuring the binding of an anti-CD 15 antibody followed 
by FITC-conjugated anti-murine IgG antibody. Control values ob-
tained from samples incubated only with the FITC-labeled antibody 
were subtracted. 
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not seen. A 48 h incubation with either inducer led to a stron-
ger increase than 24 h of incubation (data not shown). 
In addition, the effect of simultaneous treatment of Molt-4 
cells with both inducers was investigated: 0.5 or 1.0 ng/ml 
PMA and 0.5 or 1.0 mg/ml Thymex-L did not augment 
CD 15 expression over the level reached with either of the 
inducers (Fig. 4). Therefore an additive or synergistic effect 
was not seen. In one combination a partial antagonism was 
even observed: 1.0 ng/ml PMA stimulated the median fluo-
rescence by 197% of the control, but in combination with 0.5 
mg/ml Thymex-L only 152% was found. 
4. Discussion 
Here we report the expression and modulation of the adhe-
sion molecule Lewis x (CD 15) in Molt-4 cells as a T cell 
model. This cell surface carbohydrate participates at the first 
step of leukocyte extravasation and reacts with its counterpart 
ligand P-selectin. The constitutive CD 15 expression is charac-
terized by an unusually broad distribution ranging from cells 
without CD 15 to cells with very high CD 15 expression. This 
was also seen with another T cell line (H9 cells). 
The thymus provides a unique environment for the develop-
ment of T cells. To modulate CD15 expression we investigated 
cytokines known to be present in the thymus and to influence 
T cell development. IL-1 is produced by stromal cells of the 
thymus [22]; its receptor has been isolated from T cells [23]. 
Also for IL-2, IFN-γ, and TNF-α functions related to T cells 
have been reported (reviewed in [24]). But none of these cy-
tokines showed a positive or a negative influence on the CD 15 
number at the Molt-4 cell surface. 
A second class of immunoregulatory substances present in 
the thymus comprises the so-called thymic peptides or hor-
mones. Isolation, characterization and elucidation of their 
functions are well documented [25,26]. Here we showed that 
a total thymus water extract has a strong enhancing effect on 
CD15 expression. Various biological activities of Thymex-L 
have been demonstrated in vitro and in vivo. Thymex-L has 
beneficial effects on depressed immunological functions of pa-
tients with disseminated cancer [27]. In lung cancer patients, 
Thymex-L enhanced the lymphoproliferative response in com-
bination with indometacin in vitro [28]. In a clinical trial, 
PMA (ng/ml) Thymex-L (mg/ml) 
Fig. 3. Dose dependence of CD 15 expression in Molt-4 cells Treat-
ment for 24 h and analysis as described in the legend to Fig. 2. 
Thymex-L (mg/ml) 0.0 0.0 0.5 1.0 0.5 1.0 0.5 1.0 
Fig. 4. CD 15 expression after 24 h of simultaneous treatment of 
Molt-4 cells with PMA and Thymex-L. The cells were analyzed as 
described in the legend to Fig. 2. 
Thymex-L showed a protective effect on lymphocytes of 
lung cancer patients who had been exposed to irradiation 
[27] and partially normalized depressed monocyte functions 
in selected melanoma patients [29]. Moreover, Thymex-L po-
tentiated the all-irans-retinoic acid-induced differentiation of 
the human cell line HL60 [30]. 
The other CD 15 activator identified in our investigation 
was PMA. The biological effects of phorbol esters are known 
to be mediated through the stimulation of protein kinase C 
(PKC) [31]. It seems likely PKC may also be involved in 
CD 15 regulation. Interestingly, the PMA effect on CD 15 ex-
pression is different in various cell lines: in the breast cancer 
cell line MDA-MB-468 CD15 was downregulated [12], in NB4 
and HL60 cells CD15 remained unchanged [13], and here we 
report an enhanced expression to our knowledge for the first 
time. 
The treatment of Molt-4 cells with PMA and Thymex-L, 
two completely different agents, resulted in similar effects. The 
change in flow cytometry was practically not distinguishable. 
The median fluorescence, a sensitive marker, was increased 
about 2-fold with PMA (1 ng/ml) and about 3.8-fold using 
Thymex-L (5 mg/ml). The number of positive cells was only 
moderately influenced, because Molt-4 cells exhibited a basal 
CD 15 expression of about 60%. Surprisingly, when both in-
ducers were used simultaneously, an additive or synergistic 
effect was not seen. This suggests that the action of the two 
substances was mediated by different pathways. It is remark-
able that for comparable effects a seemingly 106 times higher 
amount of Thymex-L than of PMA is necessary. This may be 
caused by the complex composition of the extract containing a 
variety of molecules not involved in the enhancement of CD 15 
expression. The purification of an active component may 
drastically reduce the amount in the assay. 
The physiological significance of our results remains to be 
shown. In general, an enhanced expression of adhesion mol-
ecules may be followed by a stronger cell-cell interaction. 
Granulocytes from patients with chronic myeloid leukemia 
exhibit reduced binding to P-selectin [32]. In contrast to nor-
mal granulocytes, the binding of these cells cannot be blocked 
with an anti-CD 15 antibody suggesting repressed CD 15 ex-
pression. Other reports confirming this hypothesis are avail-
able for the related sialyl Lewis x antigen. In vitro treatment 
of human gastric adenocarcinoma (NUGC4) cells with di-
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methyl sulfoxide resulted in enhanced expression of sialyl 
Lewis x and in increased adhesion to activated human endo-
thelial cells [33]. An influence of thymic proteins on adhesion 
is also known. Prothymosin ocl stimulates the binding of pe-
ripheral blood lymphocytes to human umbilical vein endothe-
lial cells in vitro [34]. This effect is mediated by an elevated 
expression of CD16, CD18, and CD56. 
It is noteworthy that none of the pure thymic peptides up to 
1200 D a was effective in the induction of CD15 expression. 
This supports the usage of extracts containing high molecular 
mass, yet uncharacterized molecules. The isolation of such 
active molecules using Molt-4 cells may lead to the discovery 
of new biomolecules. 
A standardized in vitro bioassay for Thymex-L or its com-
ponents is not available. None of the known effects described 
above was suitable for developing such an assay. The effects 
are mostly seen only on primary cells with the disadvantage of 
great cell variability. HL60 differentiation is a time consuming 
process (5 days of incubation) [30]. Our described assay using 
a well characterized cell line that gives results within 2 days 
avoids these problems. 
Our data demonstrate that a distinct thymic extract can 
modulate the expression of the cell surface molecule Lewis 
x. The expression of specific molecules on the cell surface 
regulates cellular signal recognition, signal transduction, and 
cell-cell interactions. Therefore these processes may be influ-
enced by thymic preparations. It must be elucidated further 
whether the therapeutic potential of Thymex-L is related to 
this property. 
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